+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Antiretroviral Drugs Market: Analysis By Drug Type, By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast (2013-2023)

  • ID: 4761288
  • Report
  • Region: Global
  • 230 Pages
  • Azoth Analytics
UP TO OFF
until Dec 31st 2019
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • MORE
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of antiretroviral market. The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others). The report analyses the antiretroviral market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes drug sales forecast for some antiretroviral drugs.

According to the research report “Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023”, the antiretroviral market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 – 2023.
Over the recent years, Antiretroviral drugs market has been witnessing growth on account of several driving factors including growing prevalence of HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficacy. Moreover, factors such as growing medical spending, favorable steps by government of various countries, decreased cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population has been driving the market growth of antiretroviral drugs. In addition, increasing uptake of INSTI based regimens, increasing awareness regarding HIV care and treatment procedures, new drug launches, and improved R&D pipeline are anticipated to fuel the market growth in forecasted period. However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.

In this research report, the market is segmented on the basis of drug type. By drug type, the multi-class drug combinations are predicted to hold their dominant position in the market, especially Gilead Sciences product Biktarvy and ViiV Healthcare product Triumeq are expected to give more traction to the market. Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017. The largest share of North America is attributed to high ART coverage rate and more emphasis towards prescribed branded drugs.

The report titled “Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023” has covered and analysed the potential of antiretroviral drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antiretroviral market. Additionally, the report also highlights market entry strategies for various companies across the globe along with drug sales forecast analysis.

Scope of the Report

Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antiretroviral Drugs Market– Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
  • Drug Sales Forecast:
o Multi-Class Drugs Combination: Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®.
o Nucleoside Reverse Transcriptase Inhibitors: Epzicom®/ Kivexa®.
o Non-Nucleoside Reverse Transcriptase Inhibitors: Edurant®.
o Protease Inhibitors: PREZISTA ® /PREZCOBIX® /REZOLSTA ®.
o Integrase Strand Transfer Inhibitors: Tivicay®, Isentress/Isentress HD®.
o CCR5 Inhibitor: Selzentry®/ Celsentri®.

Regional Antiretroviral Drugs Market – North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antiretroviral Drugs Market– Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
Country Analysis – U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antiretroviral Drugs Market– Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
Other Report Highlights
  • Product Sales Forecast.
  • Market Dynamics – Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • MORE
1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Antiretroviral Drugs Products Outlook

5. Global Antiretroviral Drugs Market: Growth and Forecast
5.1 By Value (2013-2017)
5.2 By Value (2018-2023)

6. Global Antiretroviral Drugs Market: Segment Analysis
6.1 Global Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
6.1.1 Global Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
6.1.2 Global Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
6.2 Global Multi-Class Drugs Combination Market Size, By Value (2013-2023)
6.3 Global NRTI Market Size, By Value (2013-2023)
6.4 Global NNRTI Market Size, By Value (2013-2023)
6.5 Global Protease Inhibitors Market Size, By Value (2013-2023)
6.6 Global Other Antiretroviral Drugs Market Size, By Value (2013-2023)
6.6 Global Antiretroviral Drugs: Market Attractiveness, By Drug Type
6.7 Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5)

7. Global Antiretroviral Drugs Market: Regional Analysis
7.1 Global Antiretroviral Drugs Market Size, By Region: Breakdown (%)
7.1.1 Global Antiretroviral Drugs Market Size, By Region, 2017 (%)
7.1.2 Global Antiretroviral Drugs Market Size, By Region, 2023 (%)

8. North America Antiretroviral Drugs Market: Growth and Forecast
8.1 North America Antiretroviral Drugs Market: Segmental Analysis
8.2 North America Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
8.2.1 North America Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
8.2.2 North America Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
8.3 North America Multi-Class Drugs Combination Market Size, By Value (2013-2023)
8.4 North America NRTI Market Size, By Value (2013-2023)
8.5 North America NNRTI Market Size, By Value (2013-2023)
8.6 North America Protease Inhibitors Market Size, By Value (2013-2023)
8.7 North America Other Antiretroviral Drugs Market Size, By Value (2013-2023)

8.9 North America Antiretroviral Drugs Market: Country Analysis (U.S and Canada)
8.9.1 U.S Antiretroviral Drugs Market, By Value (2013-2023)
8.9.2 U.S Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

8.9.3 Canada Antiretroviral Drugs Market, By Value (2013-2023)
8.9.4 Canada Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9. Europe Antiretroviral Drugs Market: Growth and Forecast
9.1 Europe Antiretroviral Drugs Market: Segmental Analysis
9.2 Europe Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
9.1.2 Europe Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
9.1.3 Europe Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
9.3 Europe Multi-Class Drugs Combination Market Size, By Value (2013-2023)
9.4 Europe NRTI Market Size, By Value (2013-2023)
9.5 Europe NNRTI Market Size, By Value (2013-2023)
9.6 Europe Protease Inhibitors Market Size, By Value (2013-2023)
9.7 Europe Other Antiretroviral Drugs Market Size, By Value (2013-2023)

9.8 Europe Antiretroviral Drugs Market: Country Analysis (Germany, France, U.K, Italy)

9.8.1 Germany Antiretroviral Drugs Market, By Value (2013-2023)
9.8.2 Germany Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.4 France Antiretroviral Drugs Market, By Value (2013-2023)
9.8.5 France Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.6 UK Antiretroviral Drugs Market, By Value (2013-2023)
9.8.7 UK Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.8 Italy Antiretroviral Drugs Market, By Value (2013-2023)
9.8.9 Italy Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10. APAC Antiretroviral Drugs Market: Growth and Forecast

10.1 APAC Antiretroviral Drugs Market: Segmental Analysis
10.2 APAC Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
10.2.1 APAC Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
10.2.2 APAC Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
10.3 APAC Multi-Class Drugs Combination Market Size, By Value (2013-2023)
10.4 APAC NRTI Market Size, By Value (2013-2023)
10.5 APAC NNRTI Market Size, By Value (2013-2023)
10.6 APAC Protease Inhibitors Market Size, By Value (2013-2023)
10.7 APAC Other Antiretroviral Drugs Market Size, By Value (2013-2023)

10.8 APAC Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
10.8.1 China Antiretroviral Drugs Market, By Value (2013-2023)
10.8.2 China Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10.8.3 Japan Antiretroviral Drugs Market, By Value (2013-2023)
10.8.4 Japan Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10.8.5 India Antiretroviral Drugs Market, By Value (2013-2023)
10.8.6 India Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

11. ROW Antiretroviral Drugs Market: Growth and Forecast
11.1 ROW Antiretroviral Drugs Market: Segment Analysis
11.2 ROW Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
11.1.1 ROW Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
11.1.2 ROW Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
11.3 ROW Multi-Class Drugs Combination Market Size, By Value (2013-2023)
11.4 ROW NRTI Market Size, By Value (2013-2023)
11.5 ROW NNRTI Market Size, By Value (2013-2023)
11.6 ROW Protease Inhibitors Market Size, By Value (2013-2023)
11.7 ROW Other Antiretroviral Drugs Market Size, By Value (2013-2023)

11.8 ROW Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
11.8.1 South Africa Antiretroviral Drugs Market, By Value (2013-2023)
11.8.2 South Africa Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

12. Global Antiretroviral Drugs Market: Market Dynamics
12.1 Global Antiretroviral Drugs Market: Drivers
12.2 Global Antiretroviral Drugs Market: Restrains
12.3 Global Antiretroviral Drugs Market: Trends
12.4 Global Antiretroviral Drugs Market: Product Benchmarking

13. Porter Five Force Analysis

14. SWOT Analysis

15. Company Profiles
15.1 Gilead Sciences
15.2 ViiV Healthcare
15.3 Bristol-Myer Squibb
15.4 AbbVie Inc.
15.5 Boehringer-Ingelheim
15.6 Johnson and Johnson
15.7 Merck & Co.
15.8 CIPLA
17.9 Merck & Co,
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Gilead Sciences Inc.
  • ViiV Healthcare
  • Bristol-Myers Squibb
  • AbbVie Inc.
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Merck & Co.
  • Cipla
  • Mylan
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll